STRATEGIC AUDIT: MERCK & CO.

Merck became a public company as a consequence of the entry of the United States into the First World War. At that time, George Merck, grandson of the founder of the German company, owned 20 percent of the equity stock in Merck (United States), while the German parent company owned 80 percent of the equity stock. George Merck retained his 20 percent of the equity stock, but transferred the 80 percent equity interest held by the German parent company to the United States government. Following the end of the First World War, the United States government sold its 80 percent share in the company to the public (HooverÆs Inc., History, 2003).

There is an aura of legal impropriety about the transfer of stock that he did not own by George Merck, and the subsequent sales of that stock by the United States government. Those actions, nevertheless, launched Merck as a public company in the United States.

In 2002, Merck recorded $51.8 billion in sales, a level that was 8.5 percent higher than the preceding year. The companyÆs $7.1 billion net profit in 2002 was a 13.7 percent return on sales, and, in dollars, was 1.8 percent higher than profits in the preceding year (Merck & Co., Inc.,

. . .
onsiders strengths, weaknesses, core competencies, and sources of competitive advantage. A SWOT analysis for Merck is presented in Exhibit 1 (located in the Appendix to this study) and the results of a financial ratio analysis are presented in Exhibit 2 (located in the Appendix to this study). Merck has a strong product line in many areas of the pharmaceutical market; however, the firm does not have a strong product line across the board. Merck has an unhealthy dependence on so-called lifestyle drugs (pharmaceuticals designed to aid in weight loss and similar worthy personal goals). These products are referred to as Medco Health products, and they contributed 58 percent of MerckÆs revenues in 2002 (refer to Exhibit 3 in the Appendix to this paper). As indicated in the SWOT analysis (Exhibit 1 in the Appendix to this paper), MerckÆs market position is weakened by this situation, and a threat to the company from competitors also is linked to this situation. MerckÆs financial performance also has weakened over the past five years (refer to Exhibit 2 in the Appendix to this paper). Of particular relevance in the context of financial performance are the deteriorations in both liquidity and profitability at Merck. While the company
. . .

Some common words found in the essay are:
Industrial Classifications, Financial Performance, Strategy Analysis, Analysis Strengths, Medco Health, Market Data, George Merck, Systems Merck, Debt/Total Assets, Contributions Product, pharmaceutical industry, merck co inc, merck co, co inc, financial performance, hooverÆs inc, appendix paper, inc 2003,  net, united government, net profit, merckÆs financial performance,   exhibit, accessed internet 2003-11-20, major competitors industry,
Approximate Word count = 2168
Approximate Pages = 9 (250 words per page)